TME 81: India Has 1.4 Billion People. Then Why Do We Import Most Plasma Medicines?
- Dr. ARUN V J
- 11 hours ago
- 5 min read
Let me ask you something strange.
You live in a country with 1.4 billion people. Millions donate blood every year. India has one of the largest populations on the planet, a growing pharmaceutical industry, and engineers who can put a rocket on the moon for less money than a Hollywood film.
And yet, when a child with immune deficiency needs a medicine made from human blood, that medicine has been flown in from Germany.
When a cancer patient needs albumin to survive surgery, that albumin was likely processed in a factory 7,000 kilometres away.
We are sitting on liquid gold. And we are giving it away for free — literally — and then buying back the refined product at 10 to 100 times the cost.
This is the story of plasma. And nobody is talking about it.
First: What Exactly Is Plasma?
Blood has four main components:
Red Blood Cells (RBCs)
White Blood Cells (WBCs)
Platelets
Plasma
Components of Plasma
Plasma itself contains:
Albumin – maintains oncotic pressure
Immunoglobulins (IVIG) – antibodies for immune disorders
Clotting Factors (VIII, IX, etc.) – critical in hemophilia
Fibrinogen
Complement proteins
Electrolytes and hormones
If blood is the vehicle, plasma is the logistics network.
Without plasma proteins, modern medicine collapses.
Click here to read more about blood components.
How Are Plasma Medicines Made?
Plasma medicines are not made from one donation.
They require:
Pooling thousands of plasma units
Cold-chain transport
Viral inactivation steps
Fractionation (Cohn or chromatography methods)
Strict GMP pharmaceutical processing
Click here to read more about plasma medicines.
The end products:
IVIG
Albumin
Factor VIII / IX concentrates
Anti-D immunoglobulin
Hyperimmune globulins
This is pharmaceutical manufacturing — not just blood banking.
That distinction matters.
The Reality: Blood Banks in India
India has around 4000 blood centres (licensed blood banks across government, private, and NGO sectors).
But here’s the real question:
How many have component separation facilities?
Roughly 60% perform component separation.
The rest still issue whole blood.
Even among those with component separation:
Many lack large-scale plasma freezing capacity.
Quality consistency varies.
Plasma often remains underutilized.
Expiry leads to discard.
So although we collect significant blood annually, we do not systematically channel surplus plasma into industrial fractionation.
That is the first gap.
Source Plasma vs Recovered Plasma
This is where most discussions stop. But we must go deeper.
Recovered Plasma
Obtained from whole blood donation.
By-product after RBCs and platelets are separated.
Source Plasma
Collected via plasmapheresis.
Donor gives plasma only.
Can donate more frequently.
Designed for fractionation industry.
Countries like:
United States
Germany
Austria
Have large-scale source plasma programs.
India largely relies on recovered plasma.
Recovered plasma volumes are unpredictable.
Source plasma allows industrial planning.
This is the second gap.
Why Is There a Shortage of Plasma-Derived Medicines in India?
1️⃣ Fragmented Collection System
Thousands of independent blood banks.
Limited aggregation.
No national plasma pooling mechanism at scale.
Volume matters in fractionation.
2️⃣ Legal Framework Restrictions
Under Indian regulations:
Paid plasma donation is prohibited.
Strict controls exist under the Drugs & Cosmetics Act.
Commercial plasma collection models (like the US) are not permitted.
Ethically defensible.
But economically limiting.
3️⃣ Limited Domestic Fractionation Capacity
India has only a handful of plasma fractionation facilities, and their capacity is insufficient relative to national demand.
Building a fractionation plant:
Costs hundreds of crores.
Requires high regulatory compliance.
Needs consistent plasma supply.
Without reliable supply, investors hesitate.
4️⃣ High Demand Growth
India has:
Increasing hemophilia diagnosis
Expanding transplant programs
Growing autoimmune disorder recognition
Larger ICU and oncology population
Demand is rising faster than infrastructure.
5️⃣ Quality and Regulatory Barriers
Fractionation-grade plasma must meet:
Strict viral testing standards
Freezing within defined time
Cold-chain integrity
Not all centres consistently meet export-level fractionation standards.
So Why Does India Import Plasma Medicines?
Because importing is currently more predictable.
Major exporting countries:
United States
Germany
Spain
have integrated plasma economies.
They collect large volumes of source plasma and process it efficiently.
India, instead of building large pooled systems, buys finished products:
IVIG
Albumin
Factor concentrates
It is operationally simpler — but strategically risky.
Plasma Is Liquid Gold — But We Treat It Like Waste
In many centres:
Plasma expires.
Surplus plasma is discarded.
No industrial channel exists.
Imagine discarding crude oil because we lack refineries.
That is what happens with plasma in parts of the system.
Click here to read more about whole blood donation vs apheresis donation.
What Can India Do?
This is where systems thinking begins.
1️⃣ Build a National Plasma Grid
Aggregate surplus plasma centrally.
Create standardized quality benchmarks.
Incentivize centres to contribute fractionation-grade plasma.
2️⃣ Expand Source Plasma Under Ethical Models
Can India explore:
Voluntary repeat plasmapheresis programs?
Strong donor health monitoring?
Non-monetary incentives?
The conversation needs maturity.
3️⃣ Public–Private Fractionation Partnerships
Encourage pharmaceutical companies to invest.
Assured plasma supply contracts.
Viability gap funding from government.
4️⃣ Upgrade Blood Centre Infrastructure
Deep freezers (-80°C or below).
Rapid plasma freezing.
Uniform testing standards.
Investment here multiplies national return.
5️⃣ Data Transparency
We need accurate national data on:
Plasma collection volume
Plasma discard rates
Fractionation utilization
Import dependence
Without measurement, reform is guesswork.
Psychological Blind Spot: Why This Issue Doesn’t Go Viral
Let’s be honest.
Plasma is invisible.
No celebrity campaign.
No dramatic imagery.
No emotional trigger like organ donation.
But for a child with primary immunodeficiency, IVIG is survival.
For a hemophilia patient, factor concentrate prevents lifelong disability.
We respond emotionally to blood donation camps.
We ignore plasma economics.
That cognitive bias delays reform.
The Strategic Question
Should a country of 1.4 billion:
With 4000+ blood centres
With growing healthcare demand
With pharmaceutical manufacturing strength
Remain dependent on imported plasma-derived medicines?
This is not about nationalism.
It is about resilience.
During global supply disruptions, imports become fragile.
Healthcare sovereignty matters.
Actionable Steps: What You Can Do
If you are:
A Healthcare Professional
Promote component therapy over whole blood.
Advocate plasma utilization discussions in CMEs.
Push institutional plasma audit mechanisms.
A Policy Enthusiast or Researcher
Study plasma discard data in your state.
Publish local utilization studies.
Encourage state-level pooling models.
A Blood Centre Leader
Upgrade freezing timelines.
Train staff on fractionation-grade standards.
Explore partnerships with fractionators.
A Citizen
Donate blood regularly.
Understand component separation.
Share awareness beyond RBC donation.
India does not lack donors.
India does not lack patients.
India does not lack pharmaceutical expertise.
What we lack is systemic integration.
Plasma is liquid gold.
But gold must be refined.
If This Made You Think Differently
Share it with:
One doctor.
One policymaker.
One medical student.
One blood centre professional.
Because awareness precedes reform.
Here We question systems.
And then we build better ones.
If you want more deep dives on blood, plasma, transfusion systems, and healthcare productivity — subscribe and revisit.
The future of transfusion medicine is not just clinical.
It is strategic.
And strategy begins with thinking beyond the obvious.
Comments